Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%

Healthcare

Page 116
  1. Oct 21, 2025 · 07:00 · MSCL

    Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy

    Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy

    01
  2. Oct 21, 2025 · 04:20 · NARA

    Pangenomic expands Nara.Care with DNA program launch

    Pangenomic expands Nara.Care with DNA program launch

    02
  3. Oct 21, 2025 · 03:27 · 4565

    Nxera's Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

    Nxera's Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

    03
  4. Oct 21, 2025 · 03:05 · BNXT

    BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study

    BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study

    04
  5. Oct 20, 2025 · 20:00 · NARA

    PanGenomic Health Expands NaraCare.AI Platform with Launch of DNA Testing Program

    PanGenomic Health Expands NaraCare.AI Platform with Launch of DNA Testing Program

    05
  6. Oct 20, 2025 · 19:39 · BIOV

    BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS

    BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS

    06
  7. Oct 20, 2025 · 18:20 · QNTM

    Quantum Biopharma warrants issued to funds expire

    Quantum Biopharma warrants issued to funds expire

    07
  8. Oct 20, 2025 · 17:23 · BCT

    Briacell presents phase 3 biomarker data at ESMO 2025

    Briacell presents phase 3 biomarker data at ESMO 2025

    08
  9. Oct 20, 2025 · 17:15 · DHT

    DRI Healthcare buys royalty interest in thyroid drugs

    DRI Healthcare buys royalty interest in thyroid drugs

    09
  10. Oct 20, 2025 · 16:04 · ZYUS

    ZYUS Life Sciences Corporation Announces Closing of Additional Secured Loan

    ZYUS Life Sciences Corporation Announces Closing of Additional Secured Loan

    10
  11. Oct 20, 2025 · 12:03 · SONA

    Sona Nanotech sees 80% response in cancer study

    Sona Nanotech sees 80% response in cancer study

    11
  12. Oct 20, 2025 · 09:00 · ZCT

    Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

    Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

    12
  13. Oct 20, 2025 · 09:00 · VHI

    VitalHub Announces Q3 2025 Conference Call Date

    VitalHub Announces Q3 2025 Conference Call Date

    13
  14. Oct 20, 2025 · 08:30 · QNTM

    Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

    Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

    14
← Newer Older →